Percy H. Carter

3.6k total citations
59 papers, 1.5k citations indexed

About

Percy H. Carter is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Percy H. Carter has authored 59 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 28 papers in Molecular Biology and 22 papers in Immunology. Recurrent topics in Percy H. Carter's work include Chemokine receptors and signaling (20 papers), Chemical Synthesis and Analysis (12 papers) and Immune Cell Function and Interaction (11 papers). Percy H. Carter is often cited by papers focused on Chemokine receptors and signaling (20 papers), Chemical Synthesis and Analysis (12 papers) and Immune Cell Function and Interaction (11 papers). Percy H. Carter collaborates with scholars based in United States, Germany and Sweden. Percy H. Carter's co-authors include Thomas J. Gardella, David A. Evans, Joëlle Prunet, Erick M. Carreira, André B. Charette, Mark Lautens, Michael D. Luck, Masaru Shimizu, Carl P. Decicco and Andrew J. Tebben and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Percy H. Carter

59 papers receiving 1.4k citations

Peers

Percy H. Carter
James J.‐W. Duan United States
Toshio Furuya Japan
Robert J. Cherney United States
Guido Bold Switzerland
Denzil Bernard United States
Raymond E. Moellering United States
Pier F. Cirillo United States
Juan I. Luengo United States
Andrea Cavazzoni Italy
Semiramis Ayral‐Kaloustian United States
James J.‐W. Duan United States
Percy H. Carter
Citations per year, relative to Percy H. Carter Percy H. Carter (= 1×) peers James J.‐W. Duan

Countries citing papers authored by Percy H. Carter

Since Specialization
Citations

This map shows the geographic impact of Percy H. Carter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Percy H. Carter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Percy H. Carter more than expected).

Fields of papers citing papers by Percy H. Carter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Percy H. Carter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Percy H. Carter. The network helps show where Percy H. Carter may publish in the future.

Co-authorship network of co-authors of Percy H. Carter

This figure shows the co-authorship network connecting the top 25 collaborators of Percy H. Carter. A scholar is included among the top collaborators of Percy H. Carter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Percy H. Carter. Percy H. Carter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dodd, Dharmpal S., Honghe Wan, Shana Posy, et al.. (2020). Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9). ACS Medicinal Chemistry Letters. 11(9). 1751–1758. 30 indexed citations
2.
Jiang, Bin, James J.‐W. Duan, Arun Kumar Gupta, et al.. (2020). Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonists. Bioorganic & Medicinal Chemistry Letters. 30(17). 127392–127392. 9 indexed citations
3.
Duan, James J.‐W., Bin Jiang, Zhonghui Lu, et al.. (2020). Discovery of 2,6–difluorobenzyl ether series of phenyl ((R)–3–phenylpyrrolidin–3–yl)sulfones as surprisingly potent, selective and orally bioavailable RORγt inverse agonists. Bioorganic & Medicinal Chemistry Letters. 30(19). 127441–127441. 4 indexed citations
4.
Carter, Percy H., Joseph A. DiMasi, Ernst R. Berndt, & Mark Trusheim. (2016). Investigating investment in biopharmaceutical R&D. DSpace@MIT (Massachusetts Institute of Technology). 3 indexed citations
5.
Bhide, Rajeev S., Zheming Ruan, Carolyn A. Weigelt, et al.. (2016). Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3Kδ inhibitors. Bioorganic & Medicinal Chemistry Letters. 26(17). 4256–4260. 12 indexed citations
6.
Shi, Qing, Douglas G. Batt, Michael A. Galella, et al.. (2015). Discovery and synthesis of cyclohexenyl derivatives as modulators of CC chemokine receptor 2 activity. Bioorganic & Medicinal Chemistry Letters. 26(2). 662–666. 2 indexed citations
7.
Yang, Michael G., Zili Xiao, Qing Shi, et al.. (2011). Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2). Bioorganic & Medicinal Chemistry Letters. 22(3). 1384–1387. 2 indexed citations
8.
Carter, Percy H. & Qihong Zhao. (2010). Clinically validated approaches to the treatment of autoimmune diseases. Expert Opinion on Investigational Drugs. 19(2). 195–213. 21 indexed citations
9.
Carter, Percy H.. (2010). Spiroindenes and spiroindanes as antagonists of CC chemokine receptor 2: WO 2009023754. Expert Opinion on Therapeutic Patents. 20(2). 283–289. 5 indexed citations
10.
Cherney, Robert J., Ruowei Mo, Gengjie Yang, et al.. (2008). Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists. Bioorganic & Medicinal Chemistry Letters. 19(3). 597–601. 15 indexed citations
11.
Carter, Percy H., Rui‐Qin Liu, William R. Foster, et al.. (2007). Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe. Proceedings of the National Academy of Sciences. 104(16). 6846–6851. 22 indexed citations
12.
Gardner, Daniel S., Joseph B. Santella, Andrew J. Tebben, et al.. (2007). From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists. Bioorganic & Medicinal Chemistry Letters. 18(2). 586–595. 9 indexed citations
13.
Carter, Percy H., Robert J. Cherney, Andrew J. Tebben, et al.. (2007). Capped diaminopropionamide–glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2). Bioorganic & Medicinal Chemistry Letters. 17(19). 5455–5461. 15 indexed citations
14.
Voss, Matthew E., Percy H. Carter, Andrew J. Tebben, et al.. (2003). Both 5-arylidene-2-thioxodihydropyrimidine-4,6(1H,5H)-diones and 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones are light-Dependent tumor necrosis factor-α antagonists. Bioorganic & Medicinal Chemistry Letters. 13(3). 533–538. 58 indexed citations
15.
Carter, Percy H., et al.. (2003). A new synthesis of cytoxazone and its diastereomers provides key initial SAR information. Bioorganic & Medicinal Chemistry Letters. 13(7). 1237–1239. 32 indexed citations
16.
Carter, Percy H.. (2002). Chemokine receptor antagonism as an approach to anti-inflammatory therapy: ‘just right’ or plain wrong?. Current Opinion in Chemical Biology. 6(4). 510–525. 48 indexed citations
17.
Carter, Percy H. & Thomas J. Gardella. (2001). Zinc(II)-mediated enhancement of the agonist activity of histidine-substituted parathyroid hormone(1–14) analogues. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1538(2-3). 290–304. 4 indexed citations
18.
19.
Shimizu, Masaru, Percy H. Carter, & Thomas J. Gardella. (2000). Autoactivation of Type-1 Parathyroid Hormone Receptors Containing a Tethered Ligand. Journal of Biological Chemistry. 275(26). 19456–19460. 32 indexed citations
20.
Luck, Michael D., Percy H. Carter, & Thomas J. Gardella. (1999). The (1–14) Fragment of Parathyroid Hormone (PTH) Activates Intact and Amino-Terminally Truncated PTH-1 Receptors. Molecular Endocrinology. 13(5). 670–680. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James J.‐W. Duan Breakdown of academic impact, for papers by Toshio Furuya Breakdown of academic impact, for papers by Robert J. Cherney Breakdown of academic impact, for papers by Guido Bold Breakdown of academic impact, for papers by Denzil Bernard Breakdown of academic impact, for papers by Raymond E. Moellering Breakdown of academic impact, for papers by Pier F. Cirillo Breakdown of academic impact, for papers by Juan I. Luengo Breakdown of academic impact, for papers by Andrea Cavazzoni Breakdown of academic impact, for papers by Semiramis Ayral‐Kaloustian
Rankless by CCL
2026